Skip to main content
. Author manuscript; available in PMC: 2017 Jul 31.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2016 May 3;19(3):264–270. doi: 10.1038/pcan.2016.12

Table 2.

Ki67 analysis as a continuous variable: Multivariable Cox proportional hazard models for RFS, OS, and DSS.

Model Factor Comparison Hazard Ratio 95% LCL 95% UCL Overall p-value
RFS Model 1 (N = 634, #Events = 281) Ki67% weighted average 1% increase 1.07 1.03 1.11 0.0008
Margin Pos vs. Neg 1.41 1.09 1.84 0.01
Seminal vesicle invasion Yes vs. No 1.85 1.23 2.80 0.003
Gleason score 3+4 vs. 6 1.22 0.90 1.66 0.005
4+3 vs. 6 1.88 1.33 2.66
8–10 vs. 6 1.42 0.96 2.09
Pathologic stage pT3/pT4 vs. pT2 1.43 1.07 1.92 0.02
Log(PSA) 1 unit increase 1.62 1.35 1.96 <.0001
RFS Model 2 (N = 634, #Events = 281) Ki67% maximum 1% increase 1.04 1.01 1.07 0.007
Margin Pos vs. Neg 1.40 1.08 1.83 0.01
Seminal vesicle invasion Yes vs. No 1.85 1.22 2.79 0.004
Gleason score 3+4 vs. 6 1.24 0.91 1.67 0.003
4+3 vs. 6 1.91 1.35 2.70
8–10 vs. 6 1.46 0.99 2.15
Pathologic stage pT3/pT4 vs. pT2 1.44 1.07 1.93 0.02
Log(PSA) 1 unit increase 1.61 1.34 1.95 <.0001
OS (N = 984, #Events = 57) Ki67% positive 1% increase 1.09 1.01 1.16 0.02
Gleason Score 3+4 vs. <=6 0.87 0.44 1.72 0.68
4+3 vs. <=6 1.14 0.46 2.84 0.78
8–10 vs. <=6 3.28 1.65 6.51 0.0007
DSS (N = 874, #Events = 44) Ki67% positive 1% increase 1.10 1.02 1.18 0.02
Log(PSA) 1 unit increase 1.98 1.35 2.89 0.005
Gleason Score 3+4 vs. <=6 2.27 0.93 5.52 0.07
4+3 vs. <=6 2.75 0.97 7.81 0.06
8–10 vs. <=6 5.13 1.92 13.75 0.001

Recurrence free survival (RFS) event is defined as any recurrence, metastasis, or prostate cancer death. Models 1 and 2 are separate models using Ki67 weighted average % positive (PI=2.19) and maximum % positive (PI=3.11), respectively. Overall survival (OS) event is defined as death of any cause. Disease-specific survival (DSS) event is defined as prostate cancer metastasis or death due to PC. Both OS and DSS have only one final model. Only significant factors were included in the final models.